Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)
- Poster presentation
- Open Access
AKT inhibition mitigates terminal differentiation and preserves central memory phenotype of CD8 T cells
Journal for ImmunoTherapy of Cancer volume 2, Article number: P93 (2014)
CD8 T cell response comprises effector and memory T cells. Effector CD8 T cells become terminally differentiated and are eliminated by apoptosis. Memory CD8 T cells encompass central (TCM) and effector memory T cells (TEM). TCM display a higher proliferative ability, express a higher level of CD62L and are superior in their protection against viral and bacterial challenges and mediation of anti-tumor immunity when compared to TEM. The differentiation of CD8 T cell is thought to be coordinated by the PI3K/Akt pathway.
The effect of in vitro Akt inhibition using the pan Akt inhibitors MK-2206 and AZD5363 on the differentiation and proliferation of CD8 T cells was examined. Cell proliferation, expansion, cytokine production and phenotype were assessed in antigen specific CD8 T cells.
We found that the inhibition of Akt leads to a significant enhancement of the proliferative potential of CD8 T cells, and to prolongation of their survival upon TCR re-stimulation. Furthermore, we found that Akt inhibition leads to increase in IL-2 secretion, a marker of cells with high proliferative ability. We further identified that Akt inhibition preserved the TCM phenotype by conserving a higher percentage of (CD44HI CD62LHI) expressing T cells. These cells also displayed a higher level of CD127 and a lower level of the exhaustion marker KLRG-1 reflecting their increased expansion ability and longevity due to Akt inhibition. Additionally, we found that Akt inhibition also resulted in the preservation of a significantly higher percentage of naïve CD8 T cells (CD44LO CD62LHI) when compared to the non-treated cells.
Here, we show that Akt inhibition preserves the central memory phenotype of CD8 T cells thus enhancing their proliferation, survival and cytokine production. Furthermore, Akt inhibition results in the conservation of a reservoir of naïve CD8 T cells. Both naïve and TCM CD8 T cells are superior mediators of anti-tumor immunity when compared to effector or TEM cells. These findings strongly suggest the utility of using Akt inhibitors to modulate the immune response as part of cancer immune therapy.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Abu Eid, R., Friedman, K., Mkrtichyan, M. et al. AKT inhibition mitigates terminal differentiation and preserves central memory phenotype of CD8 T cells. j. immunotherapy cancer 2 (Suppl 3), P93 (2014). https://doi.org/10.1186/2051-1426-2-S3-P93
- Immune Therapy
- Bacterial Challenge
- Expansion Ability
- High Proliferative Ability
- Central Memory Phenotype